

Supplemental Figure 1. *Akt1^{-/-}* and *Akt2^{-/-}* T cells display an opposing capacity in producing IL-17, IFN- γ , and GM-CSF, but not IL-10, IL-6, and IL-12p40

(A) WT, $Akt1^{-/-}$ and $Akt2^{-/-}$ mice (n = 8) were immunized with MOG₃₅₋₅₅ in CFA and 8 days later the mice were sacrificed. The draining lymph node cells were cultured with MOG₃₅₋₅₅ peptide (20 µg/ml) for 72 h. The supernatants collected from these cultures were subjected to ELISA for IL-17, IFN- γ , IL-6, and GM-CSF, IL-10 and IL12p40. (B) *Tcrb*^{-/-} mice receiving WT, *Akt1*^{-/-} or *Akt2*^{-/-} CD4⁺ T cells (n = 5) were immunized with MOG₃₅₋₅₅ in CFA. The recipient mice were sacrificed at day 10. The draining lymph node cells were cultured with MOG₃₅₋₅₅ peptide (20 µg/ml) for 72 h. The supernatants collected from these cultures were subjected to ELISA for IL-17, IFN- γ , IL-6, and GM-CSF, IL-10 and IL12p40. The data shown are one representative of three independent experiments. Student t test. * p<0.05,** p<0.01,*** p<0.001



Supplemental Figure 2. The major T cells that contribute to inflammatory cytokines by $Akt1^{-/-}$, and $Akt2^{-/-}$ mice during EAE induction are Teffs and not Tregs

WT, $Akt1^{-/-}$, and $Akt2^{-/-}$ mice (n= 4) were immunized with MOG₃₅₋₅₅ in CFA and 8 days later the mice were sacrificed. The draining lymph node cells stimulated with PMA/ionomycin, surface-stained with anti-CD4, anti-CD25, and intracellularly stained with anti-Foxp3 Ab, together with anti-IL-17, anti-IFN- γ , anti-IL-6, and anti-TNF- α Abs, respectively. The expression of these cytokines in CD4⁺CD25⁺Foxp3⁺ Tregs and CD4⁺Foxp3⁻ Teffs as determined by flow cytometry.



Supplemental Figure 3. Activated Akt-1 and Akt-2, as well as total Akt-1 and Akt-2 are differentially expressed in CD4⁺CD25⁺Foxp3⁺ Tregs upon immunization with MOG₃₅₋₅₅ in CFA.

(A) Tregs were isolated from thymuses of WT mice (n = 3) at the steady state, and the expressions of Akt-1 and Akt-2 in these Tregs were assessed by immuniblotting. (B) WT mice (n = 3) immunized with MOG₃₅₋₅₅ in CFA were sacrificed on day 3 and 7 after immunization (w Imm). The cells in the draining lymph nodes were surface-stained with anti-CD4, anti-CD25, and intracellularly stained with anti-Foxp3 and anti-Helios, together with anti-phospho-Akt-1, and anti-phospho-Akt-2. (C) WT mice (n = 3) immunized with MOG₃₅₋₅₅ in CFA were sacrificed on day 3 and 7 after immunization (w Imm). The cells in the draining lymph nodes were surface-stained with anti-CD4 and 7 after immunization (w Imm). The cells in the draining lymph nodes were surface-stained with anti-CD4 and anti-CD25, and intracellularly stained with anti-Foxp3, together with anti-Akt-1, or anti-Akt-2. WT mice without immunization (w/o imm) were used as controls. The data showed are one representative of three independent experiments.



Supplemental Figure 4. $Akt1^{-/-}$ and $Akt2^{-/-}$ Teffs do not suppress EAE development in *Tcrb*^{-/-} mice receiving naive CD4⁺ T cells Naïve CD4⁺CD44^{low}CD62L^{hi}CD25⁻ T cells from WT mice together with CD4⁺CD25⁻ T cells from WT, $Akt1^{-/-}$, or $Akt2^{-/-}$ mice were transferred into *Tcrb*^{-/-} mice (n = 4 per group) which were then immunized with MOG₃₅₋₅₅ in CFA. The development of EAE was monitored. The data shown are one representative of two independent experiments.